LINK BETWEEN PREMATURE CARDIOVASCULAR DISEASE AND HYPERHOMOCYSTEINEMIA

Authors

  • Khadija Kiran Department of Physiology, Gujranwala Medical College, Gujranwala, Pakistan
  • Mahwash Malik Department of Pharmacology, Central Park Medical College, Lahore, Pakistan
  • Sabahat Fatima Department of Biochemistry, Gujranwala Medical College, Gujranwala, Pakistan
  • Farah Naz Tahir Department of Biochemistry, Central Park Medical College, Lahore, Pakistan
  • Jazib Andleeb Department of Physiology, CMH Institute of Medical Sciences, Bahawalpur, Pakistan
  • Haroon Habib Department of Biochemistry, Avicenna Medical College, Lahore, Pakistan
  • Haiqa Ashraf Central Park Medical College, Lahore, Pakistan

DOI:

https://doi.org/10.69656/pjp.v20i3.1699

Keywords:

Homocysteine, hyperhomocysteinemia, premature cardiovascular disease, early diagnosis.

Abstract

Background: Hyperhomocysteinemia, characterized by elevated homocysteine levels, is recognized as a significant risk factor for premature cardiovascular disease (CVD) due to its role in endothelial dysfunction and atherogenesis. This study aims to measure the homocysteine concentration in CVD patients and determine the link between homocysteine levels and premature CVD. Methods: This prospective cohort study was conducted on 350 subjects after their consent and randomly selected after approval by the IRB. The sample size was calculated using OpenEpi. In the experimental group, 200 patients with unstable angina, non-ST, and ST-elevation myocardial infarction were included. After 10 hours of fasting, blood samples were taken and homocysteine concentrations were measured with an ELISA kit (Rochester). Wilcoxon test was applied and p?0.05 was considered significant. Results: Most of the subjects fell in older age groups. Family history of CVD was present in 41% of patients, 48% had non-ST and ST-elevation MI, 7% were post-myocardial infarction, and 3% patients had recurrent myocardial infarction. There was an increased concentration of homocysteine in the experimental groups compared to controls (25±0.1 µmol/L vs 5.71±0.2 µmol/L). The differences were more significant in ST elevation than in other conditions and the control group. Conclusion: Homocysteine levels were elevated in CVD with the highest concentration observed in ST-elevation MI. It is important to monitor homocysteine levels in patients with a family history of cardiovascular disease or a history of myocardial infarction. Elevated homocysteine levels may be useful biomarker for assessing cardiovascular risk.

Pak J Physiol 2024;20(3):74-6,  DOI: https://doi.org/10.69656/pjp.v20i3.1699

Downloads

Download data is not yet available.

References

Liu J, Quan J, Li Y, Wu Y, Yang L. Blood homocysteine levels could predict major adverse cardiac events in patients with acute coronary syndrome. Medicine (Baltimore) 2018;97(40):e12626.

McCully KS. Homocysteinemia and arteriosclerosis. Am Heart J 1972;83(4):571–3.

Habib SS, Al-Khlaiwi T, Almushawah A, Alsomali A, Habib SA. Homocysteine as a predictor and prognostic marker of atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2023;27(18):8598–608.

Unadkat SV, Padhi BK, Aparna Bhongir V, Gandhi AP, Shamim MA, Dahiya N, et al. Association between homocysteine and coronary artery disease –trend over time and across the regions: a systematic review and meta-analysis. Egypt Heart J 2024;76(1):29.

Ranjbari S, Jamialahmadi T, Arefinia R, Sahebkar A. Detecting homocysteine in cardiovascular disease using aptasensors: A review. Sens Actuators Rep 2023;6:100178.

Jean-Louis Gueant, Rosa-Maria Guéant-Rodriguez, Oussalah A, Zuily S, Rosenberg I. Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials. Thromb Haemost 2022;123(3):270–82.

Kumar a, Sharma P, Kumar P, Kumar DA. Homocysteine: a newer and novel independent risk factor and cardiac marker for acute MI. Asian J Pharm Clin Res 2019;12(3):177–80.

Filip C, Albu E, Ion H, Filip C, Magda C, Florin Popa R, et al. Is homocysteine a marker or a risk factor: A question still waits for an answer. In: Filip N, Elena Iancu C, (Eds). Non-Proteinogenic Amino Acids. IntechOpen; 2018.p.33–51.

Smith AD, Refsum H. Homocysteine –from disease biomarker to disease prevention. J Intern Med 2021;290(4):826–54.

Zhang Z, Gu X, Fang X, Tang Z, Guan S, Liu H, et al. Homocysteine and the risk of cardiovascular events and all-cause death in elderly population: A community-based prospective cohort study. Ther Clin Risk Manag 2020;16:471–81.

Singla H, Panag KMD, Batta A, Goyal G. Homocysteine levels in patients of type 2 diabetes mellitus with diabetic nephropathy and its clinical implications. Int J Med Res Rev 2015;3(9):1070–6.

Wang B, Mo X, Wu Z, Guan X. Systematic review and meta-analysis of the correlation between plasma homocysteine levels and coronary heart disease. J Thorac Dis 2022;14(3):646–53.

Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension 2019;75(2):285–92.

Yuan S, Mason AM, Carter P, Burgess S, Larsson SC. Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. BMC Med 2021;19(1):97.

Downloads

Published

30-09-2024

How to Cite

1.
Kiran K, Malik M, Fatima S, Tahir FN, Andleeb J, Habib H, et al. LINK BETWEEN PREMATURE CARDIOVASCULAR DISEASE AND HYPERHOMOCYSTEINEMIA. Pak J Phsyiol [Internet]. 2024 Sep. 30 [cited 2024 Dec. 4];20(3):74-6. Available from: https://www.pjp.pps.org.pk/index.php/PJP/article/view/1699